Search

Your search keyword '"Mackensen, Andreas"' showing total 1,325 results

Search Constraints

Start Over You searched for: Author "Mackensen, Andreas" Remove constraint Author: "Mackensen, Andreas"
1,325 results on '"Mackensen, Andreas"'

Search Results

2. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

4. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

5. The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany

7. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

10. A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS.

13. Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

14. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

15. Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma

17. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers

18. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis

22. The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany

23. Detection of signature double‐negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function

25. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up

28. Calibration of the carbon isotope composition (δ13C) of benthic foraminifera

32. Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center

34. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

35. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study

38. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

39. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

40. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

42. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

43. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

46. Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY

48. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

Catalog

Books, media, physical & digital resources